Castillo J, Curley J, Hotz J, Uezono M, Tigner J, Chasin M, Wilder R, Langer R, Berde C
Department of Anesthesia, Children's Hospital, Boston, Massachusetts, USA.
Anesthesiology. 1996 Nov;85(5):1157-66. doi: 10.1097/00000542-199611000-00025.
Previous work showed that incorporation of dexamethasone (0.05 weight/weight percentage) into bupivacaine microspheres prolonged blockade by eight to 13 times compared with that produced by bupivacaine microspheres alone. The determinants of dexamethasone's block-prolonging effect were examined and reported here.
Polylactic-co-glycolic acid polymer microspheres (65/35) with 75 weight/weight percentage bupivacaine were prepared. Microspheres were injected adjacent to the rat sciatic nerve, and sensory and motor blockade were assessed. A procedure was developed to test drugs for block-prolonging ability in vivo by placing test drugs in the injection fluid along with a suspension of bupivacaine microspheres.
Dexamethasone alone in suspension did not produce blockade, nor did it prolong blockade induced by aqueous bupivacaine. Bupivacaine microspheres (150 mg drug/kg rat weight) produced blockade for 6 to 10 h. Dexamethasone in the suspending solution of microspheres prolonged block by up to five times. Glucocorticoids prolonged block in proportion to glucocorticoid/antiinflammatory potency. The corticosteroid antagonist cortexolone inhibited dexamethasone's blockade-prolonging action. Durations of blockade with or without dexamethasone were unaltered by hydroxyurea-induced neutrophil depletion. Microspheres were extracted from rats at time points ranging from 7 h to 7 days, and residual microsphere dry weight and bupivacaine content were similar in groups of rats injected with either bupivacaine microspheres or bupivacaine microspheres containing dexamethasone, respectively.
Glucocorticoids prolong blockade from bupivacaine microspheres. The mechanism appears unrelated to the kinetics of bupivacaine release in vivo.
先前的研究表明,与单独使用布比卡因微球相比,将地塞米松(0.05重量/重量百分比)掺入布比卡因微球可使神经阻滞时间延长8至13倍。本文研究并报告了地塞米松延长神经阻滞作用的决定因素。
制备含75重量/重量百分比布比卡因的聚乳酸-乙醇酸共聚物微球(65/35)。将微球注射到大鼠坐骨神经附近,评估感觉和运动阻滞情况。开发了一种程序,通过将测试药物与布比卡因微球悬浮液一起置于注射液中,来测试药物在体内延长神经阻滞的能力。
单独悬浮的地塞米松不会产生神经阻滞,也不会延长布比卡因水溶液诱导的神经阻滞。布比卡因微球(150mg药物/大鼠体重)产生6至10小时的神经阻滞。微球悬浮液中的地塞米松可将神经阻滞延长至五倍。糖皮质激素延长神经阻滞的时间与糖皮质激素/抗炎效力成正比。皮质类固醇拮抗剂皮质酮抑制地塞米松的神经阻滞延长作用。羟基脲诱导的中性粒细胞减少对有无地塞米松时的神经阻滞持续时间无影响。在7小时至7天的时间点从大鼠体内提取微球,注射布比卡因微球或含地塞米松的布比卡因微球的大鼠组中,残留微球干重和布比卡因含量相似。
糖皮质激素可延长布比卡因微球的神经阻滞时间。其机制似乎与布比卡因在体内的释放动力学无关。